BioCentury | Mar 9, 2017
Financial News

XTL completes private placement

...Autoimmune company XTL Biopharmaceuticals Ltd. (NASDAQ:XTLB; Tel Aviv:XTL) raised $2.8 million through the sale of 1.4 million ADSs...
...ADSs at $2.30. Each ADS represents 100 ordinary shares. XTL Biopharmaceuticals Ltd. (NASDAQ:XTLB; Tel Aviv:XTL), Raanana, Israel Alex Himes XTL Biopharmaceuticals Ltd....
BioCentury | Feb 24, 2017
Financial News

XTL completes direct public offering

...Autoimmune company XTL Biopharmaceuticals Ltd. (NASDAQ:XTLB; Tel Aviv:XTL) raised $2.5 million through the sale of 1 million ADSs...
...ADSs at $4.10. H.C. Wainwright was the placement agent. XTL Biopharmaceuticals Ltd. (NASDAQ:XTLB; Tel Aviv:XTL), Raanana, Israel Alex Himes XTL Biopharmaceuticals Ltd....
BioCentury | Jan 11, 2016
Financial News

XTL proposes follow-on

...XTL Biopharmaceuticals Ltd. (NASDAQ:XTLB; Tel Aviv:XTL), Herzliya, Israel Business: Cancer, Neurology, Infectious Date announced: 2015-12-31 Type...
BioCentury | Apr 6, 2015
Financial News

XTL completes direct public offering

...XTL Biopharmaceuticals Ltd. (NASDAQ:XTLB; Tel Aviv:XTL), Herzliya, Israel Business: Cancer, Neurology, Infectious Date completed: 2015-03-31 Type...
BioCentury | Jun 16, 2014
Financial News

XTL financial update

...independent directors. The company said it plans to remedy the deficiency. *** XTL Biopharmaceuticals Ltd. (NASDAQ:XTLB; Tel Aviv:XTL...
BioCentury | Jan 20, 2014
Company News

XTL, Weizmann Institute of Science deal

...Yeda Research and Development Co. Ltd., the institute's technology transfer company, granted XTL exclusive, worldwide rights...
...British Isles Lupus Assessment Group (BILAG) index or the SLE Responder Index (SRI), according to XTL...
...expects to begin a Phase II trial (see BioCentury, Sept. 24, 2007). XTL Biopharmaceuticals Ltd. (NASDAQ:XTLB; Tel Aviv:XTL...
BioCentury | Jul 22, 2013
Financial News

XTL financial update

...a level II ADR program. Each ADR represents 20 ordinary shares. *** XTL Biopharmaceuticals Ltd. (NASDAQ:XTLB; Tel Aviv:XTL...
BioCentury | Jul 15, 2013
Financial News

XTL financial update

...in "the coming weeks." Each ADR is equivalent to 20 ordinary shares. XTL Biopharmaceuticals Ltd. (Pink:XTLBY; Tel Aviv:XTL...
BioCentury | May 27, 2013
Finance

Demand disequilibrium

...would be profitable in 2012. It ended up posting an operating loss for the year. XTL Biopharmaceuticals Ltd....
...and has since been preparing for a Phase II trial. In its recent 20-F filing, XTL...
...Israel Moberg Pharma AB (SSE:MOB), Bromma, Sweden PharmaLundensis AB (AktieTorget:PHAL), Lund, Sweden XTL Biopharmaceuticals Ltd. (Pink:XTLBY; Tel Aviv:XTL...
BioCentury | Dec 3, 2012
Company News

Proteologics, Teva, XTL deal

...biopharmaceuticals company Proteologics from Teva at NIS1.41 per share, or about NIS6.5 million ($1.7 million). XTL...
...businesses that do not fit and partner pipeline assets that are not in core areas. XTL...
...Tel Aviv:PRTL), Orangeburg, N.Y. Teva Pharmaceutical Industries Ltd. (NYSE:TEVA), Petah Tikva, Israel XTL Biopharmaceuticals Ltd. (Pink:XTLBY; Tel Aviv:XTL...
Items per page:
1 - 10 of 183
BioCentury | Mar 9, 2017
Financial News

XTL completes private placement

...Autoimmune company XTL Biopharmaceuticals Ltd. (NASDAQ:XTLB; Tel Aviv:XTL) raised $2.8 million through the sale of 1.4 million ADSs...
...ADSs at $2.30. Each ADS represents 100 ordinary shares. XTL Biopharmaceuticals Ltd. (NASDAQ:XTLB; Tel Aviv:XTL), Raanana, Israel Alex Himes XTL Biopharmaceuticals Ltd....
BioCentury | Feb 24, 2017
Financial News

XTL completes direct public offering

...Autoimmune company XTL Biopharmaceuticals Ltd. (NASDAQ:XTLB; Tel Aviv:XTL) raised $2.5 million through the sale of 1 million ADSs...
...ADSs at $4.10. H.C. Wainwright was the placement agent. XTL Biopharmaceuticals Ltd. (NASDAQ:XTLB; Tel Aviv:XTL), Raanana, Israel Alex Himes XTL Biopharmaceuticals Ltd....
BioCentury | Jan 11, 2016
Financial News

XTL proposes follow-on

...XTL Biopharmaceuticals Ltd. (NASDAQ:XTLB; Tel Aviv:XTL), Herzliya, Israel Business: Cancer, Neurology, Infectious Date announced: 2015-12-31 Type...
BioCentury | Apr 6, 2015
Financial News

XTL completes direct public offering

...XTL Biopharmaceuticals Ltd. (NASDAQ:XTLB; Tel Aviv:XTL), Herzliya, Israel Business: Cancer, Neurology, Infectious Date completed: 2015-03-31 Type...
BioCentury | Jun 16, 2014
Financial News

XTL financial update

...independent directors. The company said it plans to remedy the deficiency. *** XTL Biopharmaceuticals Ltd. (NASDAQ:XTLB; Tel Aviv:XTL...
BioCentury | Jan 20, 2014
Company News

XTL, Weizmann Institute of Science deal

...Yeda Research and Development Co. Ltd., the institute's technology transfer company, granted XTL exclusive, worldwide rights...
...British Isles Lupus Assessment Group (BILAG) index or the SLE Responder Index (SRI), according to XTL...
...expects to begin a Phase II trial (see BioCentury, Sept. 24, 2007). XTL Biopharmaceuticals Ltd. (NASDAQ:XTLB; Tel Aviv:XTL...
BioCentury | Jul 22, 2013
Financial News

XTL financial update

...a level II ADR program. Each ADR represents 20 ordinary shares. *** XTL Biopharmaceuticals Ltd. (NASDAQ:XTLB; Tel Aviv:XTL...
BioCentury | Jul 15, 2013
Financial News

XTL financial update

...in "the coming weeks." Each ADR is equivalent to 20 ordinary shares. XTL Biopharmaceuticals Ltd. (Pink:XTLBY; Tel Aviv:XTL...
BioCentury | May 27, 2013
Finance

Demand disequilibrium

...would be profitable in 2012. It ended up posting an operating loss for the year. XTL Biopharmaceuticals Ltd....
...and has since been preparing for a Phase II trial. In its recent 20-F filing, XTL...
...Israel Moberg Pharma AB (SSE:MOB), Bromma, Sweden PharmaLundensis AB (AktieTorget:PHAL), Lund, Sweden XTL Biopharmaceuticals Ltd. (Pink:XTLBY; Tel Aviv:XTL...
BioCentury | Dec 3, 2012
Company News

Proteologics, Teva, XTL deal

...biopharmaceuticals company Proteologics from Teva at NIS1.41 per share, or about NIS6.5 million ($1.7 million). XTL...
...businesses that do not fit and partner pipeline assets that are not in core areas. XTL...
...Tel Aviv:PRTL), Orangeburg, N.Y. Teva Pharmaceutical Industries Ltd. (NYSE:TEVA), Petah Tikva, Israel XTL Biopharmaceuticals Ltd. (Pink:XTLBY; Tel Aviv:XTL...
Items per page:
1 - 10 of 183